About: Progress in the development of virus-like particle vaccines against respiratory viruses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Progress in the development of virus-like particle vaccines against respiratory viruses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Progress in the development of virus-like particle vaccines against respiratory viruses
Creator	Quan, Fu-Shi Kang, Sang-Moo Basak, Swarnendu Chu, Ki-Back Kim, Sung
Source	Medline; PMC
abstract	Introduction: Influenza virus, human respiratory syncytial virus (RSV), and human metapneumovirus (HMPV) are important human respiratory pathogens. Recombinant virus-like particle (VLP) vaccines are suggested to be potential promising platforms to protect against these respiratory viruses. This review updates important progress in the development of VLP vaccines against respiratory viruses. Areas Covered: This review summarizes progress in developing VLP and nanoparticle-based vaccines against influenza virus, RSV, and HMPV. The PubMed was mainly used to search for important research articles published since 2010 although earlier key articles were also referenced. The research area covered includes VLP and nanoparticle platform vaccines against seasonal, pandemic, and avian influenza viruses as well as RSV and HMPV respiratory viruses. The production methods, immunogenic properties, and vaccine efficacy of respiratory VLP vaccines in preclinical animal models and clinical studies were reviewed in this article. Expert opinion: Previous and current preclinical and clinical studies suggest that recombinant VLP and nanoparticle vaccines are expected to be developed as promising alternative platforms against respiratory viruses in future. Therefore, continued research efforts are warranted.
has issue date	2020-01-18(xsd:dateTime)
bibo:doi	10.1080/14760584.2020.1711053
bibo:pmid	31903811
has license	no-cc
sha1sum (hex)	179e23cae17b70aab44cef424080cf37832c3e3f
schema:url	https://doi.org/10.1080/14760584.2020.1711053
resource representing a document's title	Progress in the development of virus-like particle vaccines against respiratory viruses
has PubMed Central identifier	PMC7103727
has PubMed identifier	31903811
schema:publication	Expert Rev Vaccines
resource representing a document's body	covid:179e23cae17b70aab44cef424080cf37832c3e3f#body_text
is schema:about of	named entity 'VIRUS-LIKE PARTICLE VACCINES' named entity 'summarizes' named entity 'Recombinant' named entity 'viruses' named entity 'viruses' named entity 'virus-like particle' named entity 'viruses' named entity 'PUBMED' named entity 'INCLUDES' named entity 'PREVIOUS' named entity 'INTRODUCTION' named entity 'VLP' named entity 'COVERED' named entity 'PRECLINICAL' named entity 'REVIEWED' named entity 'PLATFORM' named entity 'RECOMBINANT VIRUS' named entity 'IMPORTANT' named entity 'ARTICLE' named entity 'ARTICLES' named entity 'RESEARCH' named entity 'PRODUCTION' named entity 'CLINICAL STUDIES' named entity 'REFERENCED' named entity 'SEASONAL' named entity 'EXPERT OPINION' named entity 'REVIEW' named entity 'POTENTIAL' named entity 'VACCINE EFFICACY' named entity 'KEY' named entity 'RESPIRATORY VIRUSES' named entity 'DEVELOPMENT' named entity 'PROGRESS' named entity 'HUMAN' named entity 'FUTURE' named entity 'RESPIRATORY' named entity 'HUMAN RESPIRATORY SYNCYTIAL VIRUS' named entity 'RSV' named entity 'RESPIRATORY VIRUSES' named entity 'AREAS' named entity 'HUMAN METAPNEUMOVIRUS' named entity 'BASED' named entity 'EARLIER' named entity 'THESE' named entity 'DEVELOPING' named entity 'INFLUENZA VIRUSES' named entity 'PUBLISHED' named entity 'DEVELOPMENT' named entity 'CONTINUED' named entity 'VIRUS-LIKE PARTICLE' named entity 'CURRENT' named entity 'IMMUNOGENIC' named entity 'NANOPARTICLE' named entity 'VACCINES' named entity 'PROGRESS' named entity 'RECOMBINANT' named entity 'PROPERTIES' named entity 'INFLUENZA VIRUS' named entity 'AVIAN INFLUENZA' named entity 'ANIMAL MODELS ' named entity 'AREA' named entity 'METHODS' named entity 'ALTERNATIVE' named entity 'RESPIRATORY PATHOGENS' named entity 'SUGGEST' named entity 'EXPECTED' named entity 'PANDEMIC' named entity 'USED' named entity 'SEARCH' covid:arg/179e23cae17b70aab44cef424080cf37832c3e3f named entity 'development' named entity 'respiratory' named entity 'respiratory' named entity 'virus' named entity 'vaccines' named entity 'articles' named entity 'Influenza virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software